Stock NRSN NEUROSENSE THERAPEUTICS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages NeuroSense Therapeutics Ltd.

Equities

NRSN

IL0011809592

Market Closed - Nasdaq
Other stock markets
 20:59:56 28/06/2024 BST 		5-day change 1st Jan Change
1.12 USD +9.80% Intraday chart for NeuroSense Therapeutics Ltd. +24.72% +42.68%
06-24 Global markets live: Novo Nordisk, Apple, UPS, Eli Lilly, Qualcomm... Our Logo
06-24 NeuroSense Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
NeuroSense Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
La zone euro veut éviter son moment Liz Truss
En Direct des Marchés : Thales, Orange, Safran, Casino, Prosus, Apple, Julius Bär, Hugo Boss...
Borsa di Italia: L'Eurozona vuole evitare il suo momento Liz Truss
Bolsa de Madrid: La eurozona quiere evitar su momento Liz Truss
NeuroSense Therapeutics Receives Delisting Notice From Nasdaq
NeuroSense Partners with PhaseV for ALS Treatment Trial -- Shares Up
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients
NeuroSense Therapeutics Ltd. and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
NeuroSense Therapeutics Ltd. Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
NeuroSense Therapeutics Prices $4.5 Million Offering of Ordinary Shares, Warrants
NeuroSense Therapeutics Ltd. Collaborates with Lonza to Identify Exosome-Based Biomarkers, in Order to Advance Neurodegenerative Disease Treatments and Diagnostics
NeuroSense Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Neurosense Therapeutics Ltd. Reports Additional Positive Results from Its ALS Phase 2B Paradigm Trial
NeuroSense Gets Non-Compliance Notice From Nasdaq
Neurosense Therapeutics Ltd. Reports Additional Positive Efficacy Data from Further Evaluation of Its Phase 2B Als Trial
NeuroSense Therapeutics Ltd.'s Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints
Top Premarket Gainers
NeuroSense Therapeutics Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Neurosense Receives U.S. Fda Confirmation of Cmc Strategy for Primec in Preparation for Pivotal Phase 3 in Als and Commercial Readiness
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NRSN Stock
  4. News NeuroSense Therapeutics Ltd.
  5. Other languages